Omnicell (OMCL) Tops Q4 EPS by 3c, Revenues Miss; Offers Q1 & FY19 EPS Mid-Point Guidance Above Consensus, Q1 Revenues Guidance Below Consensus, FY19 Revenue Outlook Tops Views

Omnicell (NASDAQ: OMCL) reported Q4 EPS of $0.70, $0.03 better than the analyst estimate of $0.67. Revenue for the quarter came in at $211.8 million versus the consensus estimate of $215.4 million.

"With the launch of our Autonomous Pharmacy vision at ASHP Midyear, health system pharmacists are understanding and embracing the need for radical change in medication management," said Randall A. Lipps, chairman, president, chief executive officer, and founder of Omnicell. "We continue to partner with our customers to drive this revolutionary, digital approach, which will help allow nurses and pharmacists to move away from manual workflows and operate at the top of their license."

GUIDANCE:

Omnicell sees Q1 2019 EPS of $0.38-$0.43, versus the consensus of $0.39. Omnicell sees Q1 2019 revenue of $196-202 million, versus the consensus of $202.28 million.

Omnicell sees FY2019 EPS of $2.40-$2.60, versus the consensus of $2.42. Omnicell sees FY2019 revenue of $880-900 million, versus the consensus of $876.4 million.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• U.S. Physical Therapy names Nchacha Etta as CFO, effective Sept. 2026
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Z Squared outlines AI power strategy and Paradox Data acquisition